Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2011
04/20/2011EP2311952A2 Antibodies to MRT-1 protein or fragments thereof
04/20/2011EP2311951A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
04/20/2011EP2311950A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
04/20/2011EP2311944A1 Polypeptides and polynucleotides from coagulase-negative staphylococci
04/20/2011EP2311943A2 Factor VII glycoforms
04/20/2011EP2311882A1 Reducing the immunogenicity of fusion proteins
04/20/2011EP2311872A1 Albumin fusion proteins
04/20/2011EP2311870A1 Compositions and methods for the treatment of immune related diseases
04/20/2011EP2311869A1 Use of mammalian cytokine; related reagents
04/20/2011EP2311868A1 Compositions and methods for the treatment of immune related diseases
04/20/2011EP2311867A1 Trimeric binding proteins for trimeric cytokines
04/20/2011EP2311866A1 GAG binding proteins
04/20/2011EP2311864A1 Recombinant protein-s composition
04/20/2011EP2311863A1 Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
04/20/2011EP2311862A2 Differential in tumour gene products and use of same
04/20/2011EP2311861A2 Differential in tumour gene products and use of same
04/20/2011EP2311860A2 Differential in tumour gene products and use of same
04/20/2011EP2311854A1 Mutated pseudomonas exotoxins with reduced antigenicity
04/20/2011EP2311852A1 Anti-infarction molecules
04/20/2011EP2311851A2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
04/20/2011EP2311850A1 Anti-cancer cyclopenta[g]quinazoline compounds
04/20/2011EP2311849A1 Specific binding agents of human angiopoietin-2
04/20/2011EP2311532A1 Anti-viral griffithsin compounds, compositions, and methods of use
04/20/2011EP2311531A1 Anti-viral griffithsin compounds, compositions, and methods of use
04/20/2011EP2311495A1 Vascularization inhibitors
04/20/2011EP2311490A2 Uses of antibodies to aminophospholipids for cancer treatment
04/20/2011EP2311486A1 GLP-2 for use in intestine and muscle recovery
04/20/2011EP2311485A1 Thymosin beta 4 promotes wound repair
04/20/2011EP2311484A1 Use of IL-12 and IL-12 antagonists for the manufacture of a pharmaceutical composition for the treatment of autoimmune diseases
04/20/2011EP2311483A1 GCSF for use in treating a neurological disease with pathophysiological mechanisms involving ischemia or hypoxia
04/20/2011EP2311482A1 Osteogenic synthetic BMP-7 peptides, pharmaceutical compositions cell culture medium containing same
04/20/2011EP2311481A2 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
04/20/2011EP2311480A1 Compstatin analogs with improved activity
04/20/2011EP2311479A1 Compstatin analogs with improved activity
04/20/2011EP2311478A1 Use of ip3 receptor-binding protein for controlling intracellular pH
04/20/2011EP2311477A1 Use of ip3 receptor-binding protein for controlling phosphatidylinositol metabolism
04/20/2011EP2311471A2 Regeneration and augmentation of bone using mesenchymal stem cells
04/20/2011EP2311469A2 Methods and compositions for tissue regeneration
04/20/2011EP2311468A1 Gene overexpressed in cancer
04/20/2011EP2311460A1 Oxymorphone controlled release formulations
04/20/2011EP2311437A1 Stabilised compositions of factor VII polypeptides
04/20/2011EP2311436A1 Stabilized protein crystals, formulations containing them and methods of making them
04/20/2011EP2311432A1 Prevention and reduction of blood loss
04/20/2011EP2311323A1 Compositions and methods for degradation of protein deposits and prions
04/20/2011EP2310523A1 Methods for enhanced production of bone morphogenetic proteins
04/20/2011EP2310509A1 Tnfsf single chain molecules
04/20/2011EP2310508A1 Tgf-b antagonist multi-target binding proteins
04/20/2011EP2310417A1 Oxidized ldl specific antibody-fusion and conjugated proteins
04/20/2011EP2310408A2 Thyroid stimulating hormone fusion proteins
04/20/2011EP2310405A1 Peptide inhibitors of cd40l signaling and uses therefor
04/20/2011EP2310402A1 Bridged secondary amines and use thereof as iap bir domain binding compounds
04/20/2011EP2310095A1 Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
04/20/2011EP2310062A1 Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness
04/20/2011EP2310061A2 Isolated extracellular matrix material including subserous fascia
04/20/2011EP2310054A2 Aptamer inhibition of thrombus formation
04/20/2011EP2310044A2 Anti-tumor immunotherapy
04/20/2011EP2310043A1 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
04/20/2011EP2310042A1 Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
04/20/2011EP2310041A2 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
04/20/2011EP2310040A1 Method to stimulate immune function and regeneration
04/20/2011EP2310039A1 Fgf-9 and its use relating to blood vessels
04/20/2011EP2310038A2 Treatment of hearing and balance impairments using compounds having erythropoietin activity
04/20/2011EP2310037A2 Conglutin-gamma as medicament and diet supplement
04/20/2011EP2310036A1 System for the determination of molecules altering the function of interferon, method therefor and compounds altering interferon activity
04/20/2011EP2310035A2 Fibroblast growth factor (fgf) analogs and uses thereof
04/20/2011EP2310034A2 Compounds for treating beta-amyloidoses
04/20/2011EP2310033A2 Compounds for treating amyloidoses
04/20/2011EP2310032A2 Compounds for treating symptoms associated with parkinson's disease
04/20/2011EP2310031A1 Combination of a tiliroside and a peptide
04/20/2011EP2310030A2 Novel antiviral peptides against influenza virus
04/20/2011EP2310029A2 Suppression of cancers
04/20/2011EP2310028A2 Suppression of neuroendocrine diseases
04/20/2011EP2310018A1 Use of nifurtimox for treating giardiasis
04/20/2011EP2309982A2 Controlled release copolymer formulation with improved release kinetics
04/20/2011EP2309979A1 Delivery of dry formulations of octreotide
04/20/2011EP2309975A2 Use of plant-derived recombinant growth factors in skin care
04/20/2011EP1938774B1 Medical artificial nerve graft containing silk fibroin and its preparation method
04/20/2011EP1670926B1 Modified cea /b7 vector
04/20/2011EP1648485B1 Formulation for a protein pharmaceutical without added human serum albumin (hsa)
04/20/2011EP1578361B1 Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
04/20/2011EP1572734B1 Peptides impairing pbx dependent gene regulation
04/20/2011EP1511471B9 Colloidal suspension of submicronic particles for delivering active principles and method for preparing same
04/20/2011EP1505963B1 Hepatitis c virus inhibitors
04/20/2011EP1082415B1 Methods useful for modulation of angiogenesis using tyrosine kinase src
04/20/2011EP1000167B2 Production of human mutant proteins in human cells by homologous recombination
04/20/2011CN1964737B Methods of using IL-1 antagonists to treat autoinflammatory disease
04/20/2011CN1849395B HLA-a24 binding cancer antigen peptide derived from ribin
04/20/2011CN1701117B Antibody against enzyme specifically cleaving VON WILLEBRAND factor and assay system using the same
04/20/2011CN102027123A Recombinant production of authentic human proteins using human cell expression systems
04/20/2011CN102027122A A method for the production of a human protein in a plant, in particular a human recombinant lysosomal enzyme in a cereal endosperm
04/20/2011CN102027114A Articular cartilage gene therapy with recombinant vector encoding BMP-7
04/20/2011CN102027110A Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
04/20/2011CN102027007A Long-acting Y2 and/or Y4 receptor agonists
04/20/2011CN102027006A Novel and powerful MHC-class II petptides derived from survivin
04/20/2011CN102026656A Method of promoting wound healing
04/20/2011CN102026655A Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
04/20/2011CN102026654A Oxygen-transferring blood substitute and a pharmaceutical composition (variants)
04/20/2011CN102026653A Human factor IX variants with an extended half life
04/20/2011CN102026652A Thrombin inhibitor
04/20/2011CN102026651A Method for achieving desired glial growth factor 2 plasma levels